AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | 2026-03-03 12:05:26 | 3.7 | -0.12 | -3.01 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCL | 0001703057 | AbCellera Biologics Inc. | CA00288U1066 | 9845000861BC95FF9F73 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | A1 | 150 W 4TH AVENUE | VANCOUVER | A1 | V5Y 1G6 | CANADA | CA | (604) 559-9005 | 150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6 | 150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6 | — | Biotechnology | 2012 | — | 596 | http://abcellera.com | 789,227,743 | 300,600,710 | 303,160,487 | AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. | 2026-02-26 18:04:55 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 789,227,743 | 118,354,062 | 17.6418 | 303,160,487 | 5,172,818 | 1.7359 |
| 2024 | 670,873,681 | -792,962,771 | -54.1702 | 297,987,669 | 5,205,517 | 1.7779 |
| 2023 | 1,463,836,452 | -2,403,087,795,548 | -99.9391 | 292,782,152 | 5,095,953 | 1.7714 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Véronique Lecault | Chief Technology Officer | 2024 | 460,000 | 184,666 | — | — | 23,040 | 3,424,564 |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary | 2024 | 460,000 | 194,580 | — | — | 30,500 | 2,890,567 |
| Carl L.G. Hansen, Ph.D. | Chief Executive Officer | 2024 | 460,000 | 263,840 | — | — | 22,996 | 8,245,492 |
| Andrew Booth | Chief Financial Officer | 2024 | 460,000 | 188,680 | — | — | 23,040 | 3,428,578 |
| Tryn Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary | 2023 | 460,000 | 180,090 | — | — | 27,600 | 667,690 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 562 |
| 2024 | 596 |
| 2023 | 586 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 75,128,000 | 28,833,000 | 38,025,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 186,829,000 | 167,259,000 | 175,658,000 |
| General And Administrative Expenses | 83,231,000 | 72,711,000 | 60,999,000 |
| Operating Expenses | 292,231,000 | 343,599,000 | 275,232,000 |
| Operating Income | -217,103,000 | -314,766,000 | -237,207,000 |
| Net Income | -146,412,000 | -162,857,000 | -146,398,000 |
| Earnings Per Share Basic | -0.49 | -0.55 | -0.51 |
| Earnings Per Share Diluted | -0.49 | -0.55 | -0.51 |
| Weighted Average Shares Outstanding Basic | 298,707,082 | 294,327,532 | 289,166,486 |
| Weighted Average Shares Outstanding Diluted | 298,707,082 | 294,327,532 | 289,166,486 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 128,513,000 | 156,325,000 | 133,320,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 39,412,000 | 31,980,000 | 0 |
| Inventories | 6,336,000 | — | — |
| Non Trade Receivables | 55,695,000 | 26,534,000 | 33,792,000 |
| Other Assets Current | 111,113,000 | 67,140,000 | 55,810,000 |
| Total Assets Current | 728,232,000 | 751,370,000 | 871,985,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 51,948,000 | 96,538,000 | 94,244,000 |
| Total Assets Non Current | 628,718,000 | 609,183,000 | 616,109,000 |
| Total Assets | 1,356,950,000 | 1,360,553,000 | 1,488,094,000 |
| Accounts Payable | 25,228,000 | 34,350,000 | 25,509,000 |
| Deferred Revenue | 13,526,000 | 13,521,000 | 18,958,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 64,307,000 | 76,612,000 | 119,013,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 4,768,000 | 1,469,000 | 5,906,000 |
| Total Liabilities Non Current | 325,739,000 | 227,857,000 | 216,763,000 |
| Total Liabilities | 390,046,000 | 304,469,000 | 335,776,000 |
| Common Stock | 802,341,000 | 777,171,000 | 753,199,000 |
| Retained Earnings | -29,482,000 | 116,930,000 | 279,787,000 |
| Accumulated Other Comprehensive Income | -4,234,000 | -4,378,000 | -1,720,000 |
| Total Shareholders Equity | 966,904,000 | 1,056,084,000 | 1,152,318,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 22,171,000 | 90,850,000 | 24,395,000 |
| Share Based Compensation Expense | 55,792,000 | 67,581,000 | 64,183,000 |
| Other Non Cash Income Expense | 3,331,000 | 19,708,000 | -277,000 |
| Change In Accounts Receivable | 55,623,000 | 75,119,000 | 45,933,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -17,148,000 | -5,954,000 | -8,980,000 |
| Change In Accounts Payable | 3,457,000 | 10,635,000 | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -131,295,000 | -108,556,000 | -43,877,000 |
| Purchases Of Marketable Securities | 436,044,000 | 765,086,000 | 1,021,510,000 |
| Sales Of Marketable Securities | 506,072,000 | 937,882,000 | 910,937,000 |
| Acquisition Of Property Plant And Equipment | 42,772,000 | 78,396,000 | 76,947,000 |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 87,750,000 | 121,409,000 | -221,108,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 14,082,000 | 12,769,000 | 10,356,000 |
| Change In Cash | -28,366,000 | 23,005,000 | -254,040,000 |
| Cash At End Of Period | 128,513,000 | 156,325,000 | 133,320,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.49 | -0.55 | -0.51 |
| Price To Earnings Ratio | -6.9796 | -5.3273 | -11.1961 |
| Earnings Growth Rate | -10.9091 | 7.8431 | -191.0714 |
| Price Earnings To Growth Ratio | 0.6398 | -0.6792 | 0.0586 |
| Book Value Per Share | 3.237 | 3.5881 | 3.985 |
| Price To Book Ratio | 1.0565 | 0.8166 | 1.4329 |
| Ebitda | -124,241,000 | -72,007,000 | -122,003,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | -0.1514 | -0.1542 | -0.127 |
| One Year Beta | 1.505 | 1.2927 | 1.3006 |
| Three Year Beta | 1.3991 | 1.3212 | 1.2268 |
| Five Year Beta | 1.3018 | 1.2287 | 1.2204 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Booth Andrew | Chief Financial Officer | 2026-02-27 | 42,600 | A | 195,600 |
| Thermopylae Holdings Ltd. | 10% owner | 2026-02-27 | 38,000 | A | 56,134,097 |
| Thermopylae Holdings Ltd. | 10% owner | 2026-02-26 | 177,457 | A | 56,096,097 |
| Lecault Veronique | Director, Chief Technology Officer | 2026-01-01 | 539,265 | A | 5,201,069 |
| Stimart Tryn | Chief Legal Officer | 2026-01-01 | 539,265 | A | 4,646,012 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 13,960 | 4,082 | 3.4199 |
| Virtu Financial LLC | 2025-12-31 | 619,000 | 181,031 | 3.4193 |
| Invesco Ltd. | 2025-12-31 | 186,742 | 54,603 | 3.42 |
| NewEdge Advisors, LLC | 2025-12-31 | 1,026 | 300 | 3.42 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 844,911 | 247,050 | 3.42 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SPDR INDEX SHARES FUNDS | 2025-12-31 | State Street(R) SPDR(R) Portfolio Developed World ex-US ETF | SPDW | 532,157 | 1,819,976.94 | 0.0054 |
| SPDR INDEX SHARES FUNDS | 2025-12-31 | State Street(R) SPDR(R) S&P(R) International Small Cap ETF | GWX | 160,957 | 550,472.94 | 0.0698 |
| NORTHERN FUNDS | 2025-12-31 | SMALL CAP VALUE FUND | NOSGX | 126,700 | 433,314 | 0.0691 |
| SMALLCAP WORLD FUND INC | 2025-12-31 | Class 529-F-3 | FSFWX | 13,361,096 | 45,694,948.32 | 0.0554 |
| SMALLCAP WORLD FUND INC | 2025-12-31 | Class 529-F-2 | FSWFX | 13,361,096 | 45,694,948.32 | 0.0554 |